GlassScriptPhysician profile
Robert Todd Hargan
NPI 1962591404
$16,128.32
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,224 · 2020: $1,871 · 2021: $2,702 · 2022: $2,895 · 2023: $3,766 · 2024: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,317 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.63 |
| Education | $118.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,263.06 | 2019-2024 | |
| Viiv Healthcare Company | $2,251.51 | 2019-2024 | Dovato, Cabenuva, Rukobia |
| Novo Nordisk INC | $1,781.00 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $1,182.02 | 2019-2024 | Pifeltro, Delstrigo, Isentress |
| Janssen Biotech, INC. | $1,095.21 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $1,023.11 | 2019-2024 | Mytesi |
| Antares Pharma, INC. | $587.58 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Theratechnologies INC. | $470.65 | 2019-2024 | Egrifta, Trogarzo, Egrifta Sv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.77 | 2019-2023 | Jardiance |
| Abbvie INC. | $419.08 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.66 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $328.83 | 2019-2023 | Farxiga |
| Pfizer INC. | $303.98 | 2019-2021 | |
| Emd Serono, INC. | $288.51 | 2019-2024 | Serostim |
| Idorsia Pharmaceuticals US INC | $189.99 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $174.41 | 2019-2020 | |
| Exact Sciences Corporation | $167.17 | 2023-2024 | Cologuard Collection Kit |
| Halozyme INC | $156.19 | 2023 | |
| Janssen Pharmaceuticals, INC | $149.79 | 2021-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $134.71 | 2023 | |
| Janssen Products, LP | $113.99 | 2019-2021 | |
| Bausch Health US, LLC | $80.67 | 2019-2022 | |
| Lilly USA, LLC | $53.93 | 2019 | |
| Astellas Pharma US INC | $21.82 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.65 | 2023 | Symtuza |
| Amgen INC. | $19.33 | 2019 | |
| Glaxosmithkline, LLC. | $15.29 | 2023 | Bexsero, Pediarix |
| Amarin Pharma, INC. | $14.57 | 2020 | |
| Esperion Therapeutics, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hargan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.